Who are the top prostate cancer specialists on Long Island?
Team leaders L. to R.: Robert Rizzo, Iwao Ojima, Martin Kaczocha, and Lloyd Trotman.
BRONX TIMES REPORTER,BTR SEPT. 11-17, 2020 17
MARISA VALENTINO
ALEXANDER EPELBAUM, M.D.
Dr. Epelbaum graduated from medical
school at New York University School
of Medicine in New York. He completed
his residency at SUNY Downstate Medical
Center in Brooklyn. He’s affi liated
with St. Catherine of Siena Medical Center
and can be reached at 631-360-7450.
ANGELO R. DEROSALIA, M.D.
Dr. DeRosalia has received multiple
awards, including the Patients’ Choice
Award (2012) and the Patients’ Choice
recognition. He has also made presentations
at national annual American
Urological Association meetings as well
as the New York Academy of Medicine.
He’s affi liated with St. Joseph Hospital
and can be reached at 516-579-6000.
ARI MOSHE BERGMAN, M.D.
Dr. Bergman attended Tufts University
School of Medicine and completed
his residency at the State University
of New York Health Science Center in
Brooklyn. He’s affi liated with Huntington
Hospital, Long Island Jewish Medical
Center, North Shore, University Hospital,
and Southside Hospital and can be
reached at 631-271-1608.
CARL MILLS, M.D.
Dr. Mills attended medical school at
George Washington University Medical
Center, Washington, D.C. He’s affi liated
with St. Charles Hospital and can
be reached at 631-509-4802.
CARLTON BARNSWELL, M.D.
Dr. Barnswell attended medical
school at Yale College. He’s affi liated
with Mercy Medical Center and can be
reached at 516-328-8775.
CHRISTOPHER ATALLA, D.O.
Dr. Atalla attended medical school at
New York College of Osteopathic Medicine
and completed his residency at
The Detroit Medical Center in Michigan.
He’s affi liated with Good Samaritan
Hospital Medical Center and can be
reached at 631-665-3737.
DAVID GOLOMBOS, M.D.
Dr. Golombos has training in open,
laparoscopic, and robotic surgery. He’s
affi liated with Stony Brook Hospital and
can be reached at 631-444-1910.
FELIX CHEUNG, M.D.
Dr. Cheung conducts research on
voiding dysfunction especially for those
who have undergone treatment for prostate
cancer and other pelvic malignancies.
His work has been published in
academic journals such as the Psychological
Bulletin and BJU International.
He’s affi liated with NYU Winthrop Hospital
and can be reached at 929-455-2700.
GREGG ZIMMERMAN, M.D.
Dr. Zimmerman completed his fellowship
in Urology at The Roswell Park
Cancer Institute. In addition to urology,
he also specializes in robotic surgery.
He’s affi liated with Mather Hospital and
can be reached at 973-627-0060.
JEFFREY HABERMAN, M.D.
Dr. Haberman is the chief of the Division
of Surgery – Urology at Plainview
Hospital and has done residencies at Lenox
Hill Hospital and Albert Einstein
Medical Center. He’s affi liated with Glen
Cove Hospital, North Shore University
Hospital, Plainview Hospital, and Syosset
Hospital and can be reached at 516-
931-1710.
LOUIS R. KAVOUSSI, M.D.
Dr. Kavoussi is the chairman of The
Arthur Smith Institute for Urology at
Northwell Health and has received multiple
awards for his work, most recently
the Ambrose Reed Lecturer Southeastern
Section, American Urological Association
award. He’s affi liated with Long
Island Jewish Valley Stream and can be
reached at 516-734-8558.
MANUEL E. GRINBERG,
M.D., F.A.C.S.
Dr. Grinberg is a member of the Suffolk
County Medical Society and American
Urologic Association, and is a Fellow
of the American College of Surgeons. He
is also fl uent in Spanish. He’s affi liated
with Brookhaven Memorial Hospital
and can be reached at 631-475-5335.
MASSIMILIANO SPALIVIERO, M.D.
Dr. Spaliviero won the Patients’
Choice Award in 2008, 2009 and 2011 as
well as the Compassionate Doctor award
in 2011. He has also conducted research
in urological oncology, prostate cancer
and bladder cancer. He’s affi liated with
Eastern Long Island Hospital and can be
reached at 631-722-2623.
MICHAEL P. HERMAN, M.D.
Dr. Herman is the director of urology
at Mount Sinai South Nassau. He
graduated magna cum laude from
Harvard University with a bachelor’s
degree in biochemical sciences and
earned a medical degree from the University
of Texas Southwestern Medical
Center. He’s affi liated with Mount Sinai
South Nassau and can be reached
at 516-632-3350.
MYKOLA ROMAN ALYSKEWYCZ,
M.D.
Dr. Alyskewycz attended New York
Medical College and completed his residency
at Montefi ore Medical Center
– Moses Division. He’s affi liated with
Glen Cove Hospital and North Shore
University Hospital and can be reached
at 516-676-2270.
PETER M. COLEGROVE, M.D.
Dr. Colegrove attended medical
school at the University of Iowa and
completed his residency at the University
of Arizona. He’s affi liated with
North Shore University Hospital and
can be reached at 847-503-3000.
REZA GHAVAMIAN, M.D.
Dr. Ghavamian speaks Spanish,
Farsi, and English, and completed his
fellowship at the Mayo Clinic. He’s
affi liated with Huntington Hospital,
Long Island Jewish Medical Center,
Peconic Bay Medical Center, Southside
Hospital, and Northwell Health
Cancer Institute. He can be reached at
631) 271-1608.
SARAH K. GIRARDI, M.D.
Dr. Girardi attended medical
school at the University of North Carolina
At Chapel Hill School of Medicine
in Chapel Hill, North Carolina.
She’s affi liated with St. Francis Hospital
and can be reached at 516-627-
6188.
STEVEN SOBEY, M.D.
Dr. Sobey specializes in general
urology, minimally invasive surgery,
and stone disease. He’s affi liated with
Southampton Hospital and can be
reached at 631-287-8600.
SBU prostate cancer treatment
research shows promise
JUSTIN CAPERA
A Stony Brook University-led research
team is investigating a new
prostate cancer treatment that could
offer an alternative to chemotherapy
without the adverse effects on patients
or tumors building up a resistance.
The research is testing a fatty
acid-binding protein (FABP) in the
treatment of infl ammation, pain,
and halting the spread of certain
cancers as drug targets themselves,
or in combination with chemotherapy
treatments such as docetaxel or
cabazitaxel, a class of drugs known
as taxanes.
“In our research, neither docetaxel
or cabazitaxel alone was able
to eradicate prostate cancer cells
in vitro, while combinations of taxanes
with FABP5 inhibitors resulted
in complete prostate cell death with
synergism at very low concentrations
of taxanes,” said Iwao Ojima,
Ph.D., the lead investigator and director
of SBU’s Institute of Chemical
Biology and Drug Discovery.
The study, in collaboration with
Artelo Biosciences, is funded by a
fi ve-year $4.2 million grant from the
National Cancer Institute (NCI). The
research seeks to advance fi ndings
from a preliminary study of FABP
and its inhibitors that earned a Fusion
Award seed grant from the Renaissance
School of Medicine at
SBU.
The original work that Ojima
and team co-leader Martin Kaczocha,
Ph.D., did with Lloyd Trotman,
Ph.D., a professor at Cold Spring
Harbor Laboratory, led to a peer-reviewed
paper published in the medical
journal The Prostate. The team
found FABP worked against highly
drug-resistant metastatic prostate
cancer cells and also enhanced the
anti-tumor effects of taxane drugs in
animal models, the researchers say.
Ojima, Kaczoha, and Trotman
are working on the project with
Robert Rizzo, Ph.D. a professor of
applied mathematics and statistics
at SBU.
”We expect to continue the momentum
of breakthroughs with our
cancer research enterprise,” said
Yusuf Hannun, M.D., director of the
SBU Cancer Center. “This expansion
of the research by Dr. Ojima
and his colleagues with new federal
funding is the type of progressive
work we hope sets the bar toward
our NCI cancer center designation
and impacts patient care in the near
future.”
For more health and wellness
coverage, visit longislandpress.
com/category/better-you